Type 2 Diabetes

Participants assigned to once-weekly tirzepatide spent significantly more time in tight target range at 52 weeks compared with those assigned to insulin degludec.

Dexamethasone as a first-line treatment for DME may increase economic costs in settings where bevacizumab is used off-label, but lower annual costs compared with aflibercept.

An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.

An analysis of the REWIND trial suggests baseline cognitive impairment was associated with a 1.6 times greater risk of major adverse cardiovascular events among patients with type 2 diabetes.

Rural patients identifying as Black had a more than 10% absolute increased risk of major leg amputation or death compared with the overall cohort with diabetic foot ulcers.

Patients from the lowest BMI, HbA1c, SBP, and LDL-C population quartile had 3.9, 3.8, 1.9, and 0.9 years of additional life expectancy, respectively.

Dr Diana Isaacs provides insight on current challenges in the clinical treatment of patients with diabetes and shares clinical pearls for the use of CGMs in disease management.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, evaluates upcoming CGM advances in the pipeline for the management of diabetes.

Analysis of the REWIND trial indicates cognitive impairment among patients with diabetes was associated with a 1.6 times greater risk of major adverse cardiovascular events and a 1.8 times greater risk of stroke or mortality.

The estimated annual progression rate to diabetes in older adults with HbA1c-defined prediabetes was 5.3%.

Pregnant women with preexisting T1D or T2D had a higher rate of any DR and a higher DR progression rate compared to the nonpregnant population.

A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.

A 12-month quality improvement project provides insight into the effects of using CGM and supplemental dietary counseling on glycemic control in adult T2D patients with suboptimal glycemic control.

From 2014 to 2020, there was significant increase in the frequency of preeclampsia or gestational hypertension, transfusion, preterm birth <37 weeks, and NICU admission.

A single-arm, open-label study provides insight into the effects of switching from multiple daily insulin injections to use of an advanced hybrid closed loop system on glycemic control in pediatric patients with type 1 diabetes.

A diet composed of healthy, plant-based foods is associated with a lower risk of developing type 2 diabetes, according to a recent study from the Harvard T.H. Chan School of Public Health.

Dr Diana Isaacs reviews the significance of Eversense’s recent approval for a 180-day indication and the potential role of Dexcom G7 in the diabetes treatment landscape.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, comments on the accuracy and selection of CGMs in treating diabetes and shares insight on the evolution of CGM systems over the past year.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Using a trio of diet indices, investigators provide insight into the relationship between adherence to plant-based diets and metabolites linked to decreased risk of type 2 diabetes.

Data from an analysis of a SWAN substudy suggests increased exposure to PFAS was linked to an increased risk of incident diabetes during midlife among women.

The study shows fenofibrate use was associated with a lower risk of progression to PDR and VTDR, but not DME alone.

The protocol appeared safe, with no associated increases in the incidence of hypoglycemic events during hospitalization or 30-day mortality.

An analysis of data from 7 US medical centers details disparities in rate of diabetic ketoacidosis among non-Hispanic Black patients compared to their White counterparts both during and before the COVID-19 pandemic.

A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.